The Generation and Down-Regulation of the Immune Response to Progressive Tumors
Determining whether a given animal or human tumor possesses antigens capable of evoking a specific antitumor immune response is essential before a rational attempt can be made to treat the tumor by a therapeutic modality designed to augment specific antitumor immunity. The role of the experimental tumor immunologists is to obtain detailed information about the immunogenicity of animal tumors and about the antitumor immune response they evoke, with a view to supplying the clinical oncologist with knowledge about the type of immune response that needs to be boosted. Regardless of whether or not animal tumors are suitable models of the human disease, the fact is that animal and human tumors have a lot in common, including the capacity to grow progressively in their hosts. Therefore, even though an animal tumor may possess tumor-specific antigens, it is not destroyed by specific or nonspecific host defense mechanisms.
KeywordsAntitumor Immunity Antitumor Immune Response Adoptive Immunotherapy Established Tumor Passive Transfer
Unable to display preview. Download preview PDF.
- 17.Takai, F., Levy, J. G., and Kilburn, D. G., 1976, In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumor bearing mice, J. Immunol. 116:288–293.Google Scholar
- 19.North, R. J., and Dye, E. S., 1985, Ly-1+2- suppressor T cells down-regulate the generation of Ly 1+2- effector T cells, Immunology 53:47–56.Google Scholar
- 23.Greene, M. I., 1980, The genetic and cellular basis of regulation of the immune response to tumor antigens, Contemp. Top. Immunobiol. 11:81–116.Google Scholar
- 39.DiGiacomo, A., and North, R. J., 1986, T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity, J. Exp. Med. 164:1179–1192.Google Scholar